Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible

BACKGROUND: The combination of bortezomib, thalidomide, and dexamethasone (VTd) is a standard of care for transplant‐eligible patients with newly diagnosed multiple myeloma (NDMM). Although approved labeling for VTd includes an escalating thalidomide dose up to 200 mg daily (VTd‐label), a lower fixe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonneveld, Pieter, Mateos, María‐Victoria, Alegre, Adrian, Facon, Thierry, Hulin, Cyrille, Hashim, Mahmoud, Vincken, Talitha, Kampfenkel, Tobias, Cote, Sarah, He, Jianming, Lam, Annette, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175866/
https://www.ncbi.nlm.nih.gov/pubmed/35845005
http://dx.doi.org/10.1002/jha2.77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175866/
https://www.ncbi.nlm.nih.gov/pubmed/35845005
http://dx.doi.org/10.1002/jha2.77

Ejemplares similares